| Non-Small Cell Lung Cancer |
1 |
1 |
| Lung Cancer |
0 |
0.95 |
| Surgery |
0 |
0.54 |
| Cancer |
0 |
0.45 |
| Small Cell Lung Cancer |
0 |
0.44 |
| Chemotherapy |
0 |
0.36 |
| Neoadjuvant Therapy |
0 |
0.99 |
| Platinum |
0 |
0.36 |
| Endometrial Cancer |
0 |
0.32 |
| Hepatocellular Carcinoma |
0 |
0.32 |
| Biliary tract cancer |
0 |
0.31 |
| Biologic Therapy |
0 |
0.29 |
| Adjuvant Setting |
0 |
0.27 |
| Acute Pain |
0 |
0.23 |
| Lung |
0 |
0.18 |
| Adverse Effects |
0 |
0.09 |
| Anaplastic Lymphoma Kinase |
0 |
0.09 |
| Anemia |
0 |
0.09 |
| Biliary Tract |
0 |
0.09 |
| Fatigue |
0 |
0.09 |
| Food and Drug Administration (FDA) |
0 |
0.09 |
| Immunotherapy |
0 |
0.09 |
| Nausea |
0 |
0.09 |
| Pain |
0 |
0.09 |
| Constipation |
0 |
0.07 |
| Pain Management |
0 |
0.07 |
| Patient Safety |
0 |
0.07 |